Credit: Novartis. The approval was based on data from the ORION-9, ORION-10, and ORION-11 trials that evaluated Leqvio in patients 18 years of age and older with HeFH or clinical ASCVD. The Food and ...

LEQVIO (inclisiran) is a first-of-its-kind therapy developed by Novartis based on small interfering RNA (siRNA) technology. It targets the mRNA of PCSK9 (proprotein convertase subtilisin/kexin type 9) ...

Novartis NVS announced new long-term data on the cholesterol-lowering drug Leqvio at the European Society of Cardiology (“ESC”) Congress 2023 in Amsterdam. Leqvio is the first and only small ...

Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C)1 4 out of 5 atherosclerotic ...

EAST HANOVER, N.J., July 10, 2023 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran) to enable earlier use in ...

A cholesterol-busting jab that is administered twice a year has the potential to transform heart care, according to its developer. It comes as new trial data suggests Leqvio, also known as inclisiran ...

With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1 Leqvio provides effective and sustained LDL-C ...

12:54, Sun, Aug 31, 2025 Updated: 12:57, Sun, Aug 31, 2025 A twice-yearly jab that combats cholesterol could revolutionise heart care, according to its creator. The drug, Leqvio, also known as ...

LEQVIO marks a significant advancement in hypercholesterolemia management, particularly for patients not achieving target LDL-C levels despite maximally tolerated statin therapy. As the first ...

Basel, December 22, 2021 — Novartis today announced the US Food and Drug Administration (FDA) approval of Leqvio ® (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower ...